Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab

Ann Oncol. 2016 Jun;27(6):1178-1179. doi: 10.1093/annonc/mdw125. Epub 2016 Apr 18.

Authors

S Cousin¹, M Toulmonde¹, M Kind², A-L Cazeau³, D Bechade⁴, J-M Coindre⁵, A Italiano⁶

Affiliations

¹ Early Phase Trials Unit; Department of Medicine.
² Department of Radiology.
³ Department of Nuclear Medicine.
⁴ Department of Medicine.
⁵ Department of Pathology, Institut Bergonié, Bordeaux, France.
⁶ Early Phase Trials Unit; Department of Medicine. Electronic address: a.italiano@bordeaux.unicancer.fr.

PMID: 27091806
DOI: 10.1093/annonc/mdw125

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects*
Antineoplastic Agents, Immunological / adverse effects*
Female
Humans
Middle Aged
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Sarcoidosis, Pulmonary / chemically induced*
Sarcoidosis, Pulmonary / diagnostic imaging*

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Programmed Cell Death 1 Receptor
pembrolizumab